- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Section 3(D) of Indian Patent Act Strikes Again
July 27, 2015 - 5:24 am
Categories:
India
News & Updates
patent infringement
Patent Opposition
Patents
pharma
Section 3(D)
0 Comments
India revoked yet another drug patent granted to a German MNC, Boehringer Ingelheim, for its respiratory drug, Spiriva (crystalline tiotropium bromide monohydrate) at a time when the US is putting pressure on the Indian government for not providing adequate patent protection to multinational drug companies. In its decision, the patent office held that Boehringer failed … Continue reading Section 3(D) of Indian Patent Act Strikes Again
Read more »Cipla & BMS may settle patent dispute over Entecavir in India
May 30, 2015 - 12:16 pm
Categories:
IPAB
IPAB Decisions
News & Updates
patent infringement
Patents
pharma
0 Comments
US-based pharma major Bristol-Myers Squibb (BMS) and Indian pharma company Cipla Ltd. are heading towards an amicable settlement on a long-stretched patent dispute concerning BMS’ hepatitis B drug Entecavir, a leading anti-viral drug for Hepatitis B patients that brings in more than a billion dollars each year globally for BMS. Entecavir, being a pre-1995 molecule, … Continue reading Cipla & BMS may settle patent dispute over Entecavir in India
Read more »Improving Regulatory Transparency for New Medical Therapies Act
A new act passed in the U.S. House of Representatives: What will it protect? Patent exclusivity, non-patent exclusivity, or both? Anything else also it deals with? The bill titled ‘A bill to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to … Continue reading Improving Regulatory Transparency for New Medical Therapies Act
Read more »Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”
April 2, 2015 - 10:04 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
patent infringement
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments
Reportedly, Hon’ble Supreme Court of India on Special Leave Petition filed by Glenmark stayed the Delhi High Court order which passed an injunction against Glenmark for the generic drug Sitagliptin till 28th April 2015. The Delhi high court dated 20th March 2015 set aside an order of a single-judge bench of Delhi High Court which … Continue reading Supreme Court stayed the Delhi High Court order of injunction against Glenmark over the Generic drug “Sitagliptin”
Read more »Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR
February 23, 2015 - 7:46 am
Categories:
IP Practice in India
News & Updates
Patents
pharma
Section 3(D)
0 Comments
Recently, the Delhi high court dated 30th January 2015 set aside an order of the Deputy Controller of Patents and Designs. The impugned order rejected a patent to US drugmaker Gilead for its hepatitis C drug “Sovaldi” on dated 13th January 2015. M/S GILEAD PHARMASSET, INC, USA, filed a patent application on 30/05/2003 in the … Continue reading Recent decision of Delhi High Court in the case of GILEAD PHARMASSET, LLC V. UNION OF INDIA & ANR
Read more »News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”
December 22, 2014 - 6:27 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
patent infringement
Patents
pharma
0 Comments
In the latest update, Novartis has sued Cipla for infringing its patents on “Onbrez” (Indacaterol) after Cipla launched its generic version for Indacaterol in October claiming “urgent unmet need” for the drug in India. Earlier, as we have reported here, Cipla approached Govt. of India to exercise its statutory powers to revoke the five patents … Continue reading News Snippet: Novartis sues Cipla for infringement of patents covering “Onbrez”
Read more »Cipla’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
December 17, 2014 - 8:25 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments
As reported in TOI, the Indian Government has found very little merit in Cipla’s plea for waiver and cancellation of Patent rights for chronic obstructive pulmonary disease (COPD) drug over which Novartis has exclusive rights. We have reported on Cipla’s plea here. Background: Cipla, previously approached the Department of Industrial Policy and Promotion (DIPP) to … Continue reading Cipla’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
Read more »Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
November 1, 2014 - 5:27 pm
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments
It has been recently reported in Economic times that Cipla has filed representation with the government (Department of Industrial Policy & Promotion) seeking revocation of five patents of Novartis on indacaterol, a respiratory drug for the treatment of chronic obstructive pulmonary disease (COPD) and marketed as Onbrez by Novartis. The central government, under section 66 … Continue reading Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
Read more »Revised Draft Guidelines for Examination of Pharma Patent Applications
August 22, 2014 - 8:23 am
Categories:
India
IP Practice in India
News & Updates
Patents
pharma
0 Comments
We have earlier reported the release of Draft Guidelines for Examination of Pharma Patent Applications. The Patent Office has now released revised draft guidelines and in continuation of our earlier article here, we explain herein what those revisions are and the impact of the guidelines in general. The revised guidelines of 12th August 2014 are … Continue reading Revised Draft Guidelines for Examination of Pharma Patent Applications
Read more »